Biomarkers of chronic airflow limitation and COPD identified by mass spectrometry.

ABSTRACT:

Rationale

COPD affects 300 million people worldwide and is the third leading cause of death according to World Health Organization global health estimates. Early symptoms are subtle, and so COPD is often diagnosed at an advanced stage. Thus, there is an unmet need for biomarkers that can identify individuals at early stages of the disease before clinical symptoms have manifested. To date, few biomarkers are available for clinical diagnostic use in COPD.

Methods

We evaluated a panel of serum biomarkers related to inflammation and infection for their ability to discriminate between 77 subjects with chronic airflow limitation (CAL) and 142 subjects with COPD, versus 150 healthy subjects (divided into two control groups that were matched with regards to age, gender and sm

SUBMITTER: Molin M 

PROVIDER: S-EPMC10860196 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature